Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMACEDO, Mariana Petaccia de
dc.contributor.authorNASCIMENTO, Ellen Caroline Toledo
dc.contributor.authorSOARES, Fernando Augusto
dc.contributor.authorSANTINI, Fernando Costa
dc.contributor.authorCOSTA, Felipe D'Almeida
dc.contributor.authorCUNHA, Isabela Werneck da
dc.contributor.authorMUNHOZ, Rodrigo Ramella
dc.contributor.authorMARCHI, Pedro De
dc.contributor.authorJORGE, Thiago William Carnier
dc.contributor.authorLEITE, Katia Ramos Moreira
dc.date.accessioned2023-10-30T14:22:28Z
dc.date.available2023-10-30T14:22:28Z
dc.date.issued2023
dc.description.abstractOncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase fusion proteins. Nevertheless, the optimal pathways and diagnostic platforms for this biomarker's screening and genomic profiling have not been defined and remain a subject of debate. A panel of national experts in molecular cancer diagnosis and treatment was convened by videoconference and suggested topics to be addressed in the literature review. The authors proposed a testing algorithm for oncogenic neurotrophic tropomyosin receptor kinase gene fusion screening and diagnosis for the Brazilian health system. This review aims to discuss the latest literature evidence and international consensus on neurotrophic tropomyosin receptor kinase gene fusion diagnosis to devise clinical guidelines for testing this biomarker. We propose an algorithm in which testing for this biomarker should be requested to diagnose advanced metastatic tumors without known driver mutations. In this strategy, Immunohistochemistry should be used as a screening test followed by confirmatory next-generation sequencing in immunohistochemistry-positive cases.eng
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipBayer
dc.identifier.citationCLINICAL PATHOLOGY, v.16, article ID 2632010X231197080, 13p, 2023
dc.identifier.doi10.1177/2632010X231197080
dc.identifier.issn2632-010X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/55936
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTDeng
dc.relation.ispartofClinical Pathology
dc.rightsopenAccesseng
dc.rights.holderCopyright SAGE PUBLICATIONS LTDeng
dc.subjectPrecision medicineeng
dc.subjectmolecular targeted therapyeng
dc.subjectbiomarkerseng
dc.subjecthigh-throughput nucleotide sequencingeng
dc.subject.otherpan-trk immunohistochemistryeng
dc.subject.othercanadian consensuseng
dc.subject.othersalivary-glandeng
dc.subject.othercancereng
dc.subject.othersensitivityeng
dc.subject.otheroncologyeng
dc.subject.otherlungeng
dc.subject.wosPathologyeng
dc.titleBrazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumorseng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalMACEDO, Mariana Petaccia de:Rede DOr Sao Luiz, Sao Paulo, Brazil; DOr Inst Res & Teaching IDOR, Sao Paulo, Brazil; Rede Or Sao Luiz, 59 Rua Bicuibas, BR-20941150 Jabaquara, SP, Brazil
hcfmusp.author.externalSOARES, Fernando Augusto:Rede DOr Sao Luiz, Sao Paulo, Brazil; DOr Inst Res & Teaching IDOR, Sao Paulo, Brazil
hcfmusp.author.externalSANTINI, Fernando Costa:Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY USA
hcfmusp.author.externalCOSTA, Felipe D'Almeida:AC Camargo Canc Ctr, Sao Paulo, Brazil; Lab DASA, Sao Paulo, Brazil
hcfmusp.author.externalCUNHA, Isabela Werneck da:Rede DOr Sao Luiz, Sao Paulo, Brazil; DOr Inst Res & Teaching IDOR, Sao Paulo, Brazil
hcfmusp.author.externalMUNHOZ, Rodrigo Ramella:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalMARCHI, Pedro De:Oncoclinicas, Rio De Janeiro, Brazil
hcfmusp.author.externalJORGE, Thiago William Carnier:Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcELLEN CAROLINE TOLEDO DO NASCIMENTO
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.description.articlenumber2632010X231197080
hcfmusp.description.volume16
hcfmusp.origemWOS
hcfmusp.origem.pubmed37719804
hcfmusp.origem.scopus2-s2.0-85171444358
hcfmusp.origem.wosWOS:001066825700001
hcfmusp.publisher.cityLONDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAdashek JJ, 2021, TRENDS CANCER, V7, P15, DOI 10.1016/j.trecan.2020.08.009eng
hcfmusp.relation.referenceAwada A, 2022, CRIT REV ONCOL HEMAT, V169, DOI 10.1016/j.critrevonc.2021.103564eng
hcfmusp.relation.referenceBebb DG, 2021, CURR ONCOL, V28, P523, DOI 10.3390/curroncol28010053eng
hcfmusp.relation.referenceBenayed R, 2019, CLIN CANCER RES, V25, P4712, DOI 10.1158/1078-0432.CCR-19-0225eng
hcfmusp.relation.referenceBruno R, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080521eng
hcfmusp.relation.referenceCallens C, 2021, JNCI-J NATL CANCER I, V113, P917, DOI 10.1093/jnci/djaa193eng
hcfmusp.relation.referenceCates JMM, 2015, APPL IMMUNOHISTO M M, V23, P471, DOI 10.1097/PAI.0000000000000111eng
hcfmusp.relation.referenceCocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0eng
hcfmusp.relation.referenceConde E, 2021, ARCH PATHOL LAB MED, V145, P1031, DOI 10.5858/arpa.2020-0400-RAeng
hcfmusp.relation.referenceCoquerelle S, 2020, VALUE HEALTH, V23, P898, DOI 10.1016/j.jval.2020.03.005eng
hcfmusp.relation.referenceDe Winne K, 2021, VIRCHOWS ARCH, V478, P283, DOI 10.1007/s00428-020-02921-6eng
hcfmusp.relation.referenceFitzgibbons PL, 2014, ARCH PATHOL LAB MED, V138, P1432, DOI 10.5858/arpa.2013-0610-CPeng
hcfmusp.relation.referenceGatalica Z, 2019, MODERN PATHOL, V32, P147, DOI 10.1038/s41379-018-0118-3eng
hcfmusp.relation.referenceGoodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49eng
hcfmusp.relation.referenceHarada G, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-00741-zeng
hcfmusp.relation.referenceHechtman JF, 2022, MODERN PATHOL, V35, P298, DOI 10.1038/s41379-021-00913-8eng
hcfmusp.relation.referenceHechtman JF, 2017, AM J SURG PATHOL, V41, P1547, DOI 10.1097/PAS.0000000000000911eng
hcfmusp.relation.referenceHondelink LM, 2022, EUR J CANCER, V173, P229, DOI 10.1016/j.ejca.2022.06.030eng
hcfmusp.relation.referenceHsiao SJ, 2019, J MOL DIAGN, V21, P553, DOI 10.1016/j.jmoldx.2019.03.008eng
hcfmusp.relation.referenceIllumina Inc, 2016, EV RNA QUAL FFPE SAMeng
hcfmusp.relation.referenceJennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011eng
hcfmusp.relation.referenceKobayashi Y, 2022, NATURE, V603, P335, DOI 10.1038/s41586-022-04451-4eng
hcfmusp.relation.referenceLim KHT, 2022, ASIA-PAC J CLIN ONCO, V18, P394, DOI 10.1111/ajco.13727eng
hcfmusp.relation.referenceLitchfield K, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107550eng
hcfmusp.relation.referenceLow SK, 2022, TRANSL LUNG CANCER R, V11, P711, DOI 10.21037/tlcr-21-981eng
hcfmusp.relation.referenceMarchiò C, 2019, ANN ONCOL, V30, P1417, DOI 10.1093/annonc/mdz204eng
hcfmusp.relation.referenceMartin FJ., NUCLEIC ACIDS RESeng
hcfmusp.relation.referenceMatsubara T, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9349132eng
hcfmusp.relation.referenceMilione M, 2017, ONCOTARGET, V8, P55353, DOI 10.18632/oncotarget.19512eng
hcfmusp.relation.referenceMiquelestorena-Standley E, 2020, MODERN PATHOL, V33, P1505, DOI 10.1038/s41379-020-0503-6eng
hcfmusp.relation.referenceMosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014eng
hcfmusp.relation.referenceMullard A, 2022, NAT REV DRUG DISCOV, V21, P548, DOI 10.1038/d41573-022-00117-yeng
hcfmusp.relation.referenceNies M., 2021, J CLIN ENDOCR METAB, V106eng
hcfmusp.relation.referenceOkamura R, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00183eng
hcfmusp.relation.referencePenault-Llorca F, 2019, J CLIN PATHOL, V72, P460, DOI 10.1136/jclinpath-2018-205679eng
hcfmusp.relation.referencePerreault S, 2021, CURR ONCOL, V28, P346, DOI 10.3390/curroncol28010038eng
hcfmusp.relation.referenceRojo Federico, 2021, Rev Esp Patol, V54, P250, DOI 10.1016/j.patol.2021.05.003eng
hcfmusp.relation.referenceRosen EY, 2020, CLIN CANCER RES, V26, P1624, DOI 10.1158/1078-0432.CCR-19-3165eng
hcfmusp.relation.referenceSociedade Brasileira de Patologia, 2020, MANUAL BOAS PRATICASeng
hcfmusp.relation.referenceSolomon JP, 2020, MODERN PATHOL, V33, DOI 10.1038/s41379-019-0324-7eng
hcfmusp.relation.referenceSolomon JP, 2019, CANCER RES, V79, P3163, DOI 10.1158/0008-5472.CAN-19-0372eng
hcfmusp.relation.referenceSolomon JP., 2019, ANN ONCOL, V30eng
hcfmusp.relation.referenceSu YJ, 2022, APPL IMMUNOHISTO M M, V30, P264, DOI 10.1097/PAI.0000000000001003eng
hcfmusp.relation.referenceSubbiah V, 2022, LANCET ONCOL, V23, P1261, DOI 10.1016/S1470-2045(22)00541-1eng
hcfmusp.relation.referenceTachon G, 2019, CANCER MED-US, V8, P7556, DOI 10.1002/cam4.2599eng
hcfmusp.relation.referenceTatematsu T, 2014, MOL CLIN ONCOL, V2, P725, DOI 10.3892/mco.2014.318eng
hcfmusp.relation.referenceTrue LD, 2008, HISTOCHEM CELL BIOL, V130, P473, DOI 10.1007/s00418-008-0481-0eng
hcfmusp.relation.referenceUhlen M., SCIENCEeng
hcfmusp.relation.referenceUkkola I, 2022, VIRCHOWS ARCH, V480, P807, DOI 10.1007/s00428-022-03302-xeng
hcfmusp.relation.referenceVendrell JA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12679-8eng
hcfmusp.relation.referencevon Ahlfen S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001261eng
hcfmusp.relation.referenceWu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938eng
hcfmusp.relation.referenceXu B, 2020, HISTOPATHOLOGY, V76, P375, DOI 10.1111/his.13981eng
hcfmusp.relation.referenceYoshino T, 2020, ANN ONCOL, V31, P861, DOI 10.1016/j.annonc.2020.03.299eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication254cbbe9-3e3c-4fb2-ba3c-3d27bb5e9355
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublication.latestForDiscovery254cbbe9-3e3c-4fb2-ba3c-3d27bb5e9355
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MACEDO_Brazilian_Expert_Consensus_for_NTRK_Gene_Fusion_Testing_2023.PDF
Tamanho:
1.21 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/26
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03